EU/3/06/411

Table of contents

About

On 31 October 2006, orphan designation (EU/3/06/411) was granted by the European Commission to Apogenix GmbH, Germany, for recombinant fusion protein consisting of the extracellular portion of CD95 fused to the Fc part of a human IgG1 molecule for the prevention of graft versus host disease.

The sponsorship was transferred to Apogenix AG - Germany, in January 2018.

Key facts

Active substance
Recombinant fusion protein consisting of the extracellular portion of CD95 fused to the Fc part of a human IgG1 molecule
Disease / condition
Prevention of graft-versus-host disease
Date of first decision
31/10/2006
Outcome
Positive
EU designation number
EU/3/06/411

Sponsor's contact details

Apogenix AG
Im Neuenheimer Feld 584
69120 Heidelberg
Germany
Tel. +49 (0) 6221 58608 0
E-mail: contact@apogenix.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating